At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 83 enrolled
Drug / intervention
Clindamycin Phosphate 1.2% And Tretinoin 0.025% Gel +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Double-Blind, Placebo-Controlled, Pilot Study to Determine the Safety and Efficacy of Clindamycin Phosphate 1.2% and Tretinoin 0.025% Gel For The Treatment of Rosacea Over 12 Weeks
In Brief
A Phase 3 clinical trial evaluating Clindamycin Phosphate 1.2% And Tretinoin 0.025% Gel and Placebo gel for Rosacea. Completed, enrolled 83 participants across 2 sites.
Detailed Summary
The purpose of this study is to determine whether Clindamycin Phosphate 1.2% And Tretinoin 0.025% Gel are effective and safe in the treatment of papulopustular rosacea.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRosacea
CountriesUnited States
CollaboratorsMedicis Pharmaceutical Corporation
Timeline
Phase 3CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedJan 2009
Enrollment StartFeb 2009
Primary CompletionOct 2010
TodayJul 2026
First PostedJan 16, 2009
Enrollment StartFeb 1, 2009
Primary CompletionOct 1, 2010
TodayJul 2, 2026
Enrollment to primary: 1.7 yearsPosted 17.5 years ago
Interventions
Clindamycin Phosphate 1.2% And Tretinoin 0.025% Geldrug
Applied on entire face (forehead, nose, cheeks, chin) once daily at night for 12 weeks
Placebo geldrug
Applied placebo gel with no active medication to entire face (forehead, nose, cheeks, chin) once daily at night for 12 weeks